E Psychedelic Drug Stocks Category Is +6% Month-To-Date

  1. Cybin (CLXPF): +27.6% (+47.3%) to $1.62/share
    • Demonstrated Proof of Concept for its deuterated tryptamine programs, CYB003 and CYB004, for the treatment of Alcohol Use Disorder that affects approximately 5.8% of adults (14.4 million adults - 9.2 million men and 5.3 million women) in the United States ages 18 and older.
  2. Field Trip (FTRPF): +11.1% (+7.7%) to $4.92/share
    • No noteworthy news.
  3. Bionomics (BNOEF): +5.6% (+5.6%) to $0.19/share
    • Completed a 1 for 6 pro rata non–renounceable entitlement offer that raised approximately A$20.4M,
    •  Novamind Inc. increased its strategic investment in Bionomics Limited to A$1,792,886 with the purchase an additional 951,133 common shares at AU$0.145 per share in Bionomics' recently completed rights offering. 
  4. Revive (RVVTF): +2.7% (N/C) @ $0.38/share
    • Filed an application with the U.S. Food and Drug Administration to receive Orphan Drug Designation for psilocybin to treat moderate to severe traumatic brain injury (approximately 50% of people with severe TBI experience further decline in their daily lives or die within 9 years of their injury and are 50x more likely to die from seizures and 6x more likely to die from pneumonia) which would qualify psilocybin for certain benefits and incentives, including seven (7) years of marketing exclusivity upon approval,
    • Applied for a U.S. provisional patent with The United States Patent and Trademark Office on an oral thin-film delivery system with psilocybin for the potential treatment of mental illness and neurological and substance abuse disorders.
  5. Numinus (LKYSF): +2.3% (+6.0%) to $0.88/share
    • Announced that the TSX Venture Exchange had accepted its 16.1M common share purchase warrants for listing under the symbol NUMI.WT.C which will entitle the holder to acquire one common share at an exercise price of $1.75 until March 19, 2023.
  6. Seelos (SEEL): +1.1% (+47.7%) to $6.32/share
    • Received a positive opinion on European Orphan Drug Designation for SLS-005 in amyotrophic lateral sclerosis (ALS) from the European Medicines Agency Committee for Orphan Medicinal Products,
    • BTIG analyst Bert Hazlett is reiterating his buy recommendation and $14 price target,
    • Signed an agreement with AptarGroup, Inc. for the co-exclusive use and supply of Aptar Pharma's Bidose Liquid System device for Seelos' intranasal ketamine product candidate, SLS-002, in the investigational development programs for the treatment of suicidality, depression, and PTSD.
  7. Jaguar (JAGX): -1.2% (+19.4%) to $1.60/share
    • Entered into a securities purchase agreement with North American institutional investors for the purchase and sale of 7,647,000 shares of common stock for gross proceeds of approximately $10.8 million in a registered direct offering for the benefit of the Company's wholly-owned Italian subsidiary, Napo EU S.p.A. 
    • Announced the upsizing by $15.3 million the at-the-market financing program with Ladenburg Thalmann & Co. Inc. for potential future financing needs,
    • Amended its Equity Purchase Agreement with Oasis Capital to purchase up to an aggregate of $2.0 million of Jaguar common stock over a 36-month period at a price of $0.436 to $3.00 and, in consideration of Oasis Capital's agreement, will issue to Oasis Capital a common stock purchase warrant to purchase 100,000 shares of the Company's common stock at a par value $0.0001 per share.
View single page >> |


Visit  munKNEE.com and register to receive our free Market Intelligence ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.